Synlogic AI Stock Analysis
Want to see SYBX full AI Analyst Report?
Synlogic (SYBX) AI Stock Analysis
Synlogic
(Other OTC:SYBX)
The overall score of 53 reflects a mixed picture. Strong technical momentum and the positive merger announcement are offset by weak financials and unattractive valuation based on current earnings. The company's lack of revenue and negative cash flow remain significant challenges, though the merger may improve its long-term prospects.
Synlogic (SYBX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 19.50K
- Price to Earnings (P/E)
- -6.0
- Beta (1Y)
- 0.71
- Revenue Growth
- ―
- EPS Growth
- 35.21%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Synlogic Business Overview & Revenue Model
Company Description
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
How the Company Makes Money
Synlogic has historically generated revenue primarily through collaboration and partnership arrangements rather than product sales, as it has been a clinical-stage company without marketed, approved therapeutics. Under such arrangements, revenue is t...
Synlogic Financial Statement Overview
Summary
Income statement is very weak (score 20) due to no revenue; balance sheet is decent (score 55) with no debt and $12M equity; cash flow remains negative but improved (score 35). Overall financial health is weak, placing the score at the lower bound.
Income Statement
20Very NegativeBalance Sheet
55NeutralCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 8,000 | 3.37M | 1.18M | 1.75M |
| Gross Profit | 0 | 0 | 8,000 | 3.37M | 1.18M | 1.75M |
| EBITDA | -5.27M | -3.53M | -23.01M | -55.31M | -63.63M | -58.12M |
| Net Income | -2.23M | -1.00M | -23.36M | -57.28M | -66.15M | -60.56M |
Balance Sheet | ||||||
| Total Assets | 11.85M | 15.45M | 19.83M | 75.55M | 110.86M | 174.74M |
| Cash, Cash Equivalents and Short-Term Investments | 11.56M | 14.67M | 18.86M | 47.75M | 77.63M | 128.59M |
| Total Debt | 0 | 0 | 0 | 17.27M | 20.30M | 20.59M |
| Total Liabilities | 1.67M | 3.58M | 7.08M | 32.90M | 28.25M | 27.47M |
| Stockholders Equity | 10.18M | 11.86M | 12.75M | 42.66M | 82.61M | 147.27M |
Cash Flow | ||||||
| Free Cash Flow | -4.03M | -4.36M | -31.67M | -51.83M | -57.62M | -52.88M |
| Operating Cash Flow | -4.03M | -4.36M | -31.66M | -51.61M | -56.89M | -52.20M |
| Investing Cash Flow | 0 | 167.00K | 25.34M | 38.77M | 58.35M | -53.25M |
| Financing Cash Flow | 1,000 | 0 | 172.00K | 20.94M | -2.04M | 89.38M |
Synlogic Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Positive. The current price of 1.07 is above the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.09, and above the 200-day MA of 0.83, indicating a bullish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.93 is Neutral, neither overbought nor oversold. The STOCH value of 64.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYBX.
Synlogic Risk Analysis
Synlogic disclosed 34 risk factors in its most recent earnings report. Synlogic reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSynlogic Peers Comparison
Overall Rating
- SYBX53Neutral
ALLR44Neutral
ICU44Neutral
LSTA42Neutral
APVO41Neutral
CING41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SYBX | 53Neutral | $13.47M | -5.99 | -19.10% | ― | ― | 35.21% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ALLR | 44Neutral | $14.54M | -0.97 | -152.77% | ― | ― | 38.64% |
| ICU | 44Neutral | $5.58M | -0.23 | -261.10% | ― | 145.74% | 75.46% |
| LSTA | 42Neutral | $13.83M | -0.64 | -113.79% | ― | -90.65% | 26.48% |
| APVO | 41Neutral | $1.19M | -0.00 | -201.49% | ― | ― | 99.41% |
| CING | 41Neutral | $65.29M | -1.03 | -238.41% | ― | ― | 37.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SYBX | Synlogic Inc | 1.07 | -0.61 | -36.39% | |
| LSTA | Lisata Therapeutics, Inc. | 1.21 | -0.88 | -42.11% | |
| APVO | Aptevo | 0.59 | -24.07 | -97.59% | |
| ICU | Seastar Medical Holding Corporation | 0.84 | -2.19 | -72.35% | |
| CING | Cingulate, Inc. | 4.30 | 0.97 | 29.13% | |
| ALLR | Allarity Therapeutics, Inc. | 0.95 | -0.17 | -14.91% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 18, 2026